Disney CEO Bob Iger admitted Marvel lost focus by overproducing for streaming and announced a shift back to high-quality theatrical films like Thunderbolts to restore the franchise's strength and drive future growth.
The review aims to enhance shareholder value, with four new independent directors joining the board. Despite a 2.7% drop in Q1 revenue, analysts raised their outlook, boosting retail sentiment.
Are you seeing these (2) ranges right now? One on the 60min, and another on the Tick Charts Put them together, and it’s easy to see why Breakout Pullbacks are my favorite trades for tomorrow!
The drugmaker’s first-quarter revenue of $41.1 million came in well below the consensus estimate of $56.7 million, attributed to changes in AbbVie’s gross-to-net rebate reserves.
Countries facing U.S. tariffs are increasingly fast-tracking Elon Musk's Starlink approvals to smooth trade ties with the Trump administration, boosting SpaceX's global expansion and driving its massive valuation growth.
Leading cryptocurrencies traded sideways on Wednesday, as the Federal Reserve warned of macroeconomic dangers from President Donald Trump’s tariff moves.
The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.
It wasn’t an inspiring day. There was a lot of back-and-forth trading, followed by a late surge on news that the Trump team plans to rescind the Biden-era AI diffusion rule and replace it with something better.
ZyVersa's IC 100 strategy focuses on targeting inflammasome-driven inflammation to enhance weight loss and improve metabolic function in obesity patients.
Jeff Bezos has long admired Sony's mission to elevate Japan's global image, and over the past 40 years, a $1,000 investment in Sony stock would have grown to more than $21,000, reflecting the company's lasting success.
With all the volatility and relentless selloffs, it’s a little surprising not to see more aggressive trade signals right now. Of the current setups, Verizon, Kinder Morgan, and Amgen stand out:
Business transformation services company Genpact (NYSE:G) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.4% year on year to $1.21 billion. On the other hand, next quarter’s revenue guidance of $1.22 billion was less impressive, coming in 2.3% below analysts’ estimates. Its non-GAAP profit of $0.84 per share was 5.8% above analysts’ consensus estimates.
Telecom software provider Amdocs (NASDAQ:DOX) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 9.4% year on year to $1.13 billion. The company expects next quarter’s revenue to be around $1.13 billion, close to analysts’ estimates. Its non-GAAP profit of $1.78 per share was 4.5% above analysts’ consensus estimates.
